middle.news
Pathkey.AI Expands AI Platform with Chipforge Acquisition and Imunexus Deal
8:06pm on Thursday 30th of April, 2026 AEST
•
Technology
Read Story
Pathkey.AI Expands AI Platform with Chipforge Acquisition and Imunexus Deal
8:06pm on Thursday 30th of April, 2026 AEST
Key Points
Launch of TrialKey Criteria Optimiser for clinical trial design
Commercial contract with Imunexus Therapeutics worth up to $100,000 plus GST
Binding agreement to acquire Singapore-based AI semiconductor company Chipforge
Completed $3.5 million capital raise to support growth and operations
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Pathkey.AI (ASX:PKY)
OPEN ARTICLE